Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan
June 12, 2024 02:55 ET
|
Belite Bio, Inc
Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related...
Technip Energies et Mitsubishi annoncent la signature d'un accord de licence pour la technologie d'alcool 'OXO M-Process'
June 10, 2024 12:05 ET
|
TECHNIP ENERGIES
Technip Energies (PARIS :TE) et Mitsubishi Chemical Corporation, filiale du groupe Mitsubishi Chemical, ont annoncé l'obtention d'une licence pour une technologie améliorée d'alcool OXO, appelée 'OXO...
Technip Energies and Mitsubishi announce licensing of improved OXO alcohol technology ’OXO M-Process’
June 10, 2024 12:05 ET
|
TECHNIP ENERGIES
Technip Energies (PARIS:TE) and Mitsubishi Chemical Corporation (Mitsubishi Chemical), a member of the Mitsubishi Chemical Group, announced that they are licensing an improved OXO alcohol technology,...
The Japanese company COLOPL takes a strategic stake of 12.5% in the capital of CBI for 12.5 million euros and entrusts it with exclusive rights to operate the Web 3.0 game Brilliantcrypto
June 07, 2024 04:30 ET
|
CRYPTO BLOCKCHAIN INDUSTRIES
The Japanese company COLOPL takes a strategic stake of 12.5% in the capital of CBI for 12.5 million euros and entrusts it with exclusive rights to operate the Web 3.0 game Brilliantcrypto COLOPL is...
ECD Auto Design Adds Black Dog Traders Branded Classic Toyota FJ SUVs to Product Lineup
June 04, 2024 08:30 ET
|
E.C.D. Automotive Design
KISSIMMEE, Fla., June 04, 2024 (GLOBE NEWSWIRE) -- ECD Automotive Design, Inc. (Nasdaq:ECDA) (“ECD” or the “Company”), the world’s largest Land Rover and Jaguar restoration company known for its...
FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors
June 03, 2024 16:02 ET
|
FibroGen, Inc.
The safety and efficacy of FG-3165 will be evaluated in a Phase 1 trial in select solid tumorsPlan to begin enrollment in 2H 2024 SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- FibroGen,...
AUROBAC THERAPEUTICS Presents its R&D Strategy & Pipeline and Announces New Development Program in Partnership with Boehringer Ingelheim
June 03, 2024 08:14 ET
|
AUROBAC THERAPEUTICS
AUROBAC THERAPEUTICS to advance ATX101 in septic shock, and multiple preclinical and discovery programs targeting Gram-negative pathogens. Lyon (France), June 3, 2024 AUROBAC THERAPEUTICS, a...
MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development
May 22, 2024 08:05 ET
|
MaxCyte, Inc
ROCKVILLE, Md., May 22, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the...
G1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective Uses
May 22, 2024 06:30 ET
|
G1 Therapeutics
G1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective Uses
Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK
May 21, 2024 08:00 ET
|
Alvotech
Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK) Alvotech will be responsible for development and...